Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion type Assertion NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_head.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion description "[These results validate myostatin inhibition as a therapeutic approach to muscle wasting diseases such as muscular dystrophy, sarcopenic frailty of the elderly and amylotrophic lateral sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_provenance.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion evidence source_evidence_literature NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_provenance.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion SIO_000772 16246158 NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_provenance.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion wasDerivedFrom befree-20140225 NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_provenance.
- NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_assertion wasGeneratedBy ECO_0000203 NP412516.RAN9CcM1Q2F-3oEapc1fXMQYEnfVx56OAPCCsda1OS_9s130_provenance.